Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Analysts

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $7.40.

A number of research firms have recently weighed in on ATNM. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Actinium Pharmaceuticals in a research note on Friday, November 15th. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Finally, Stephens reissued an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th.

Actinium Pharmaceuticals Stock Down 1.6 %

ATNM stock opened at $1.23 on Friday. The stock has a 50 day moving average of $1.60. Actinium Pharmaceuticals has a fifty-two week low of $1.16 and a fifty-two week high of $10.24. The company has a market cap of $38.37 million, a PE ratio of -0.88 and a beta of 0.07.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares during the period. Geode Capital Management LLC raised its stake in Actinium Pharmaceuticals by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after buying an additional 19,843 shares during the period. Marshall Wace LLP lifted its holdings in Actinium Pharmaceuticals by 67.9% during the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after acquiring an additional 103,557 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in Actinium Pharmaceuticals in the third quarter valued at about $322,000. Finally, XTX Topco Ltd bought a new stake in shares of Actinium Pharmaceuticals in the third quarter worth about $268,000. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).